A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.

Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer; MSI-H/dMMR Gastric Cancer Interventions: Drug: S095029; Drug: Pembrolizumab 200 mg Sponsors: Servier Bio-Innovation LLC; Merck Sharp& Dohme LLC; Institut de Recherches Internationales Servier Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials